Crohn’s patients taking Omvoh saw three-years of remission when taking Omvoh, according to new long-term data released by Eli Lilly.¹ The data is the result of the Phase 3 VIVID-2 open label extension study, which was presented at the 21^st Congress of the European Crohn’s and Colitis Organization.

What did Eli Lilly executives say about the recent Omvoh results?

In a press release, Eli Lilly executive vice president and president of Lilly Immunology Adrienne Brown said, “Too many people with inflammatory bowel disease never achieve lasting remission, leaving them vulnerable to cumulative damage from poorly controlled inflammation that can result in emergency hospitalizations or surgery. Omvoh is redefining what durable disease control can look like, with long-term data showing patients treated with Omvoh stayed in remission and experienced fewer serious complications over three years, underscoring its potential to alter the course of the disease."

In the same press release, associate professor of medicine at the University of North Carolina at Chapel Hill Edward Barnes, MD, MPH, said, “For people with Crohn's disease, unpredictable flares and abdominal pain can persist when remission isn't achieved or sustained. Additionally, ongoing symptoms like urgent trips to the bathroom and fatigue can continue to disrupt daily life when the disease is not adequately controlled. Seeing more than 90% of patients maintain steroid-free remission through three years on consistent monthly dosing, with 80% also experiencing relief from the disruptive symptoms of bowel urgency, gives providers confidence in Omvoh for outcomes that can last."

This is the latest update to Omvoh’s indications.

In October of last year,² Eli Lilly announced that FDA approved the medication as a single-injection maintenance regimen for adults with ulcerative colitis. At the time of the announcement, Lilly noted that this was the third approval for Omvoh in 2025. The drug had previously been approved for treating Crohn’s disease, along with a citrate-free formulation of the medication.

In a press release issued at the time, Miguel Regueiro, M.D., board-certified gastroenterologist specializing in inflammatory bowel disease, said, “In clinical practice, we see that simplifying maintenance treatment can make a difference in the overall patient experience. A single monthly injection of Omvoh gives patients a regimen that's easier to manage alongside the unpredictability of living with ulcerative colitis."

In the same press release, director of Crohn's and Colitis Center at OU HEALTH George Salem, MD, added, “People living with the constant discomfort and disruption caused by the symptoms of ulcerative colitis need treatments that offer the potential to achieve lasting remission and a convenient dosing option that fits easily into their lives. With this approval, patients who respond to induction therapy with Omvoh can continue maintenance therapy with the convenience of just one injection each month—delivering the same proven results with fewer injections."

"At Lilly, we are committed to supporting people living with IBD by delivering meaningful clinical outcomes and continuing to improve their treatment experience," said Ashley Diaz-Granados, senior vice president of U.S. Immunology at Lilly. "Building on the introduction of a citrate-free formulation of Omvoh earlier this year, this approval further delivers on our commitment by providing patients the same outcomes in a single-injection maintenance regimen that fits more seamlessly into their lives."

Alongside this announcement, Lilly announced the results of its Phase 3b single-arm, open label LUCENT-URGE study,³ which it says showed Omvoh provided patients with moderate to severe ulcerative colitis and bowel urgency with the following results:

• Improvements in bowel urgency severity
• Frequency of incidents
• Stool deferral time

Sources

1. Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz). Eli Lilly. February 19, 2026. https://www.prnewswire.com/news-releases/patients-with-crohns-disease-maintained-steroid-free-remission-for-three-years-with-lillys-omvoh-mirikizumab-mrkz-302691766.html
2. Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis. Eli Lilly. October 27, 2025. Accessed February 19, 2026. https://www.prnewswire.com/news-releases/lillys-omvoh-mirikizumab-mrkz-approved-by-us-fda-as-a-single-injection-maintenance-regimen-in-adults-with-ulcerative-colitis-302595733.html
3. Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis. Eli Lilly. October 27, 2025. Accessed February 19, 2026. https://www.prnewswire.com/news-releases/lillys-omvoh-mirikizumab-mrkz-demonstrated-early-and-sustained-improvement-in-bowel-urgency-outcomes-for-patients-with-ulcerative-colitis-302594395.html